146 related articles for article (PubMed ID: 38331394)
1. Association of differential censoring with survival and suboptimal control arms among oncology clinical trials.
Hsu EJ; Lin TA; Dabush DR; McCaw Z; Koong A; Lin C; Abi Jaoude J; Patel R; Kouzy R; El Alam MB; Noticewala S; Yang Y; Sherry AD; Fuller CD; Thomas CR; Tang C; Msaouel P; Das P; Huang B; Tian L; Sun R; Lee JJ; Meirson T; Ludmir EB
J Natl Cancer Inst; 2024 Jun; 116(6):990-994. PubMed ID: 38331394
[TBL] [Abstract][Full Text] [Related]
2. Informative censoring of surrogate end-point data in phase 3 oncology trials.
Gilboa S; Pras Y; Mataraso A; Bomze D; Markel G; Meirson T
Eur J Cancer; 2021 Aug; 153():190-202. PubMed ID: 34186504
[TBL] [Abstract][Full Text] [Related]
3. Equal censoring but still informative: When the reasons for censoring differ between treatment arms.
Olivier T; Prasad V
Eur J Cancer; 2024 Apr; 201():113942. PubMed ID: 38382151
[TBL] [Abstract][Full Text] [Related]
4. Censored patients in Kaplan-Meier plots of cancer drugs: An empirical analysis of data sharing.
Rosen K; Prasad V; Chen EY
Eur J Cancer; 2020 Dec; 141():152-161. PubMed ID: 33160265
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study.
Rossi A; Aimar G; Audisio M; Bungaro M; Caglio A; Di Liello R; Gamba T; Gargiulo P; Ghisoni E; Lombardi P; Marandino L; Mariniello A; Paratore C; Reale ML; Trastu F; Tuninetti V; Turco F; Fabi A; Perrone F; Di Maio M
Eur J Cancer; 2023 Aug; 189():112920. PubMed ID: 37277262
[TBL] [Abstract][Full Text] [Related]
6. The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO Trial: impact of sponsor censoring dates, drug discontinuation, and withdrawal of consent.
Serebruany VL
Cardiology; 2011; 120(3):169-71. PubMed ID: 22418766
[TBL] [Abstract][Full Text] [Related]
7. Quantifying Withdrawal of Consent, Loss to Follow-Up, Early Drug Discontinuation, and Censoring in Oncology Trials.
Wilson BE; Nadler MB; Desnoyers A; Amir E
J Natl Compr Canc Netw; 2021 Sep; 19(12):1433-1440. PubMed ID: 34479210
[TBL] [Abstract][Full Text] [Related]
8. The net benefit for time-to-event outcome in oncology clinical trials with treatment switching.
Fukuda M; Sakamaki K; Oba K
Clin Trials; 2023 Dec; 20(6):670-680. PubMed ID: 37455538
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life in trials with high rates of early censoring: Caution advised.
Olivier T; Haslam A; Prasad V
Eur J Cancer; 2024 Jul; 205():114105. PubMed ID: 38718724
[TBL] [Abstract][Full Text] [Related]
10. [Interpreting a randomized trial in oncology: Key points for the clinician].
Olivier T
Rev Med Suisse; 2024 May; 20(874):954-959. PubMed ID: 38756031
[TBL] [Abstract][Full Text] [Related]
11. Challenges, Complexities, and Considerations in the Design and Interpretation of Late-Phase Oncology Trials.
Lin TA; Sherry AD; Ludmir EB
Semin Radiat Oncol; 2023 Oct; 33(4):429-437. PubMed ID: 37684072
[TBL] [Abstract][Full Text] [Related]
12. Statistical controversies in clinical research: comparison of primary outcomes in protocols, public clinical-trial registries and publications: the example of oncology trials.
Perlmutter AS; Tran VT; Dechartres A; Ravaud P
Ann Oncol; 2017 Apr; 28(4):688-695. PubMed ID: 28011448
[TBL] [Abstract][Full Text] [Related]
13. Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?
Latimer NR; White IR; Abrams KR; Siebert U
Stat Methods Med Res; 2019 Aug; 28(8):2475-2493. PubMed ID: 29940824
[TBL] [Abstract][Full Text] [Related]
14. Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review.
Zichi C; Paratore C; Gargiulo P; Mariniello A; Reale ML; Audisio M; Bungaro M; Caglio A; Gamba T; Perrone F; Di Maio M
Eur J Cancer; 2021 May; 149():49-60. PubMed ID: 33823362
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.
Skoetz N; Bohlius J; Engert A; Monsef I; Blank O; Vehreschild JJ
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007107. PubMed ID: 26687844
[TBL] [Abstract][Full Text] [Related]
16. Self-reported conflicts of interest of authors, trial sponsorship, and the interpretation of editorials and related phase III trials in oncology.
Bariani GM; de Celis Ferrari AC; Hoff PM; Krzyzanowska MK; Riechelmann RP
J Clin Oncol; 2013 Jun; 31(18):2289-95. PubMed ID: 23630201
[TBL] [Abstract][Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
18. Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials.
Lesan V; Olivier T; Prasad V
Eur J Cancer; 2024 May; 202():114022. PubMed ID: 38547775
[TBL] [Abstract][Full Text] [Related]
19. Impact of informative censoring on the Kaplan-Meier estimate of progression-free survival in phase II clinical trials.
Campigotto F; Weller E
J Clin Oncol; 2014 Sep; 32(27):3068-74. PubMed ID: 25113767
[TBL] [Abstract][Full Text] [Related]
20. Adding new experimental arms to randomised clinical trials: Impact on error rates.
Choodari-Oskooei B; Bratton DJ; Gannon MR; Meade AM; Sydes MR; Parmar MK
Clin Trials; 2020 Jun; 17(3):273-284. PubMed ID: 32063029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
